The use of analgesics in patients that use anticoagulant and antiplatelet medications OBJECTIVES: To evaluate the use of analgesics in patients concurrently receiving anticoagulant and antiplatelet medications and determine the association with comorbidities and demographic indicators. Assess patients' knowledge of possible adverse drug interactions. STUDY DESIGN: Cross-sectional study STUDY PARTICIPANTS AND METHODS: The study included 66 adult patients who use analgesics, of whom 30 also use anticoagulants, 32 use antiplatelet medications, and 4 use both simultaneously. The study participants were surveyed in person at a family medicine office using a questionnaire that included demographic data, information on signs of bleeding, data on the frequency and type of analgesics they take, data on comorbidities, and data on knowledge of drug side effects and interactions. RESULTS: The study was conducted on 66 participants. A significant correlation was observed between the frequency of analgesic use and the occurrence of bleeding signs. Additionally, patients using ibuprofen, ketoprofen, and metamizole exhibited significantly more signs of bleeding compared to those using other analgesics. The study showed no significant difference in the occurrence of bleeding signs between participants taking non-opioid analgesics and those on a combination of opioid and non-opioid analgesics. No correlation was found between the frequency of analgesic use and participants' characteristics (gender, education level). Regarding drug side effects, 41 (62 %) participants were informed, while 12 (18 %) participants were aware of potential adverse interactions with other medications that can affect blood clotting. CONCLUSION: The study found that the frequency of analgesic use is significantly associated with the occurrence of bleeding signs in patients using medications that affect blood clotting, but not with demographic indicators. Participants demonstrated good awareness of the side effects of the medications they use, while there is room for improvement in informing patients about potential adverse drug interactions.